Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Cidara Therapeutics's share price for the quarter that ended in Dec. 2023 was $15.88. Cidara Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 4.53 Mil. Therefore, Cidara Therapeutics's market cap for the quarter that ended in Dec. 2023 was $71.94 Mil.
Cidara Therapeutics's quarterly market cap
declined
from Jun. 2023 ($101.98 Mil) to Sep. 2023 ($85.19 Mil) and
declined
from Sep. 2023 ($85.19 Mil) to Dec. 2023 ($71.94 Mil).
Cidara Therapeutics's annual market cap
declined
from Dec. 2021 ($86.19 Mil) to Dec. 2022 ($54.81 Mil) but then
increased
from Dec. 2022 ($54.81 Mil) to Dec. 2023 ($71.94 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Cidara Therapeutics's Enterprise Value for Today is $26.71 Mil.
Cidara Therapeutics Market Cap Historical Data
The historical data trend for Cidara Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cidara Therapeutics's Market Cap
For the Biotechnology subindustry, Cidara Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cidara Therapeutics's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cidara Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Cidara Therapeutics's Market Cap falls into.
Cidara Therapeutics Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Cidara Therapeutics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cidara Therapeutics (NAS:CDTX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Cidara Therapeutics Market Cap Related Terms
Thank you for viewing the detailed overview of Cidara Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Cidara Therapeutics (Cidara Therapeutics) Business Description
Cidara Therapeutics Inc is a biotechnology company. It is focused on the discovery, development, and commercialization of novel anti-infectives for the treatment and prevention of diseases. The company's Rezafungin is a novel molecule in the echinocandin class of antifungals. It is developing rezafungin for the first-line treatment and prevention of serious, invasive fungal infections which are associated with high mortality rates. Its other product candidates include CD377, CD388, RSV AVC, HIV AVC, and SARS-CoV-2 AVC.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CDTX has been successfully added to your 